EP Patent

EP3256117A4 — Methods for treating neuroblastoma

Assigned to Cancer Prevention Pharmaceuticals Inc · Expires 2018-10-10 · 8y expired

What this patent protects

Patent listed against eflornithine-hydrochloride.

Drugs covered by this patent

eflornithine-hydrochloride (EFLORNITHINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP3256117A4
Jurisdiction: EP
Classification: —
Expires: 2018-10-10
Drug substance claim: No
Drug product claim: No
Assignee: Cancer Prevention Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.